IFN-α2b efficacy is increased by administering anti-CTLA4 antibody to patients with unresectable melanoma (NC01708941) and the combination treatment utilizing Peg-IFN-α2b and the anti-PD-1 pembrolizumab are currently in clinical trials (127). The gene discussed is PDCD1; the disease is melanoma.